CSL (DB:CSJ) - Prezzo delle azioni, notizie e analisi

CSJ Panoramica delle azioni

CSJ analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	5/6
Salute finanziaria	4/6
Dividendi	4/6

Premi

Negoziato a 34.8% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 13% all'anno

Gli utili sono cresciuti del 20.4% nell'ultimo anno

Analisi del rischio

Ha un alto livello di debito

CSL Limited Concorrenti

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€857.2m

Merck KGaA

XTRA:MRK

€61.7b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.0b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per CSL
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$168.12
Massimo di 52 settimane	AU$192.00
Minimo di 52 settimane	AU$156.90
Beta	0.30
1Variazione di 1 mese	-4.25%
Variazione a 3 mesi	-10.02%
Variazione di 1 anno	6.64%
3Variazione a 3 anni	-11.15%
Variazione a 5 anni	-1.48%
Variazione dall'IPO	6,284.37%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	CSJ	DE Biotechs	DE Mercato
7D	0.1%	-1.1%	1.1%
1Y	6.6%	-18.8%	7.2%

Ritorno vs Industria: CSJ ha superato il German Biotechs che ha restituito -18.8 % nell'ultimo anno.

Rendimento vs Mercato: CSJ ha eguagliato il mercato German che ha restituito 7.2 % nell'ultimo anno.

Volatilità dei prezzi

Is CSJ's price volatile compared to industry and market?
CSJ volatility
CSJ Average Weekly Movement	2.5%
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: CSJ non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 2% ) di CSJ è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited ricerca, sviluppa, produce, commercializza e distribuisce biofarmaci e vaccini in Australia, Stati Uniti, Germania, Regno Unito, Svizzera, Cina, Hong Kong e a livello internazionale. L'azienda opera attraverso i segmenti CSL Behring, CSL Seqirus e CSL Vifor. Il segmento CSL Behring offre prodotti a base di plasma, terapie geniche e ricombinanti.

CSL Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di CSL con la sua capitalizzazione di mercato?
CSJ statistiche fondamentali
Capitalizzazione di mercato	€83.59b
Guadagni(TTM)	€2.50b
Ricavi(TTM)	€14.03b

33.9x

Rapporto P/E

6.1x

Rapporto P/S

CSJ è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CSJ Conto economico (TTM)
Ricavi	US$14.80b
Costo del fatturato	US$7.10b
Profitto lordo	US$7.71b
Altre spese	US$5.06b
Guadagni	US$2.64b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Feb 10, 2025

Utile per azione (EPS)	5.46
Margine lordo	52.06%
Margine di profitto netto	17.85%
Rapporto debito/patrimonio netto	54.2%

Come si è comportato CSJ nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.4%

Rendimento attuale del dividendo

48%

Rapporto di remunerazione

CSJ Panoramica delle azioni

Premi

Analisi del rischio

CSL Limited Concorrenti

XTRA:BIO3

€1.3b

XTRA:FYB

€857.2m

XTRA:MRK

€61.7b

NasdaqGS:REGN

US$81.0b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Now 20% undervalued

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Now 20% undervalued

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Now 20% undervalued

Now 22% undervalued

Now 20% undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 22% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold €3.3m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Now 21% undervalued after recent price drop

Independent Non-Executive Director recently bought €174k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold €4.3m worth of stock

Upcoming dividend of US$1.18 per share

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 23% undervalued

Upcoming dividend of US$1.04 per share

Now 22% undervalued after recent price drop

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.